Celcuity Inc.
Close on Oct 19, 2026
- Market cap
- $3.13B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | $-0.97 | $-0.86 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | After market close | – | $-0.97 | $-0.73 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | $-0.92 | $-0.78 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | – | $-1.04 | $-0.93 |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $0.86 | $0.81 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | $-0.85 | $-0.75 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | After market close | – | $-0.70 | $-0.65 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | – | $-0.62 | $-0.58 |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | After market close | – | $-0.64 | $-0.59 |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | After market close | – | $-0.65 | $-0.61 |
Press releases
Announcements Celcuity filed with the SEC
Celcuity Appoints David Gryska To Its Board Of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Celcuity Announces That REVTORPYK (gedatolisib) Is Now Commercially Available In The United States
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Celcuity Submits sNDA to FDA for REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K/A
EX-99.2 to Form 8-K/A
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K/A
Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Inc. Announces Public Offering of
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of Upsized Public Offering of
Material agreement · Agreement terminated · New financial obligation · Other events · EX-99.2 to Form 8-K
Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Appoints Charles Romp to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/ PIK3CA Wild-Type Advanced
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Announces Pricing of Concurrent Public Offerings of
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Concurrent Public Offerings of
Material agreement · Other events · EX-99.1 to Form 8-K
Celcuity Announces Clinically Meaningful Improvement
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of Underwritten Common Stock Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Inc. Reports First Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
18, 2023 – Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Plan to Conduct Phase 1b/2 Clinical Trial in
Other events · EX-99.1 to Form 8-K
Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer
Other events · EX-99.2 to Form 8-K
Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K